Early Metformin Use May Reduce Long COVID Risk and Mortality: Study
A study published in the Journal of Medical Virology found that COVID-19 patients prescribed metformin within six days of infection were less likely to develop long COVID or die. The findings suggest that early metformin treatment may offer a potential strategy to reduce long-term complications and mortality following SARS-CoV-2 infection. The study was conducted by Carolyn T. and colleagues.
To examine the potential association of metformin therapy initiated acutely with long-term outcomes post-infection with the virus, scientists undertook a robust new-user comparative effectiveness study, which used electronic health records (EHRs) longitudinally. In this study, adults with documented SARS-CoV-2 infection, who have documented clinic visits in 0-6 months and 6-12 months periods before being infected, but have not been treated with either metformin or control drug treatments in the last 12 months were selected.
The patients, who were on metformin within 6 days after being diagnosed with an infection, were compared with the experimental control patients receiving alternate repurposed outpatient drugs (fluvoxamine, fluticasone, ivermectin, or montelukast).
Entropy balancing technique was used to avoid any confounding by indication issue, and the number of patients after the process was 248 patients per group with the same mean age 53±16 years (16% of Black, 16% of Hispanic patients). Primary composite outcome was Long COVID (ICD-10 codes and validated computable phenotype definitions), LC/D, defined within 6-month period, examined via weighted log-linear model.
Key findings:
- Analysis with statistics based on entropy-balanced patient groups revealed substantial risk decreases and important dynamics in drug administration timings.
- Within the primary analysis of 496 balanced patients, 10 out of 248 patients (4.0%) in the early metformin arm developed Long COVID or death (LC/D), which occurred in 21 out of 248 patients (8.5%) of the comparator arm.
- The difference generated a significant adjusted risk ratio (aRR) of 0.47 (95% CI, 0.25–0.89; p=0.02), indicating that there is a 53% relative risk reduction.
- If we consider patients prescribed drugs from Days 0–1 relative to infection date, then the adjusted risk ratio will be 0.39 (95% CI, 0.12–1.24).
- When the prescription period is extended up to Days 0–14, the adjusted risk ratio is 0.75 (95% CI, 0.52–1.08).
- It can be stated that the greatest drug effectiveness takes place within the first week since infection.
- Post-weighting analysis considered well-matched patient groups at an average age of 53±16 years, among which 16% were Black and 16% – Hispanic.
To conclude, electronic health records data from the real world prove that taking metformin in the first 6 days after the SARS-CoV-2 infection reduces considerably the chance of developing Long COVID and death during 6 months. The conclusions of the research highlight the fact that outpatient prescription of metformin within 6 days is a practical solution for a 53% reduced risk of post-infection symptoms of Long COVID.
Reference:
C. T. Bramante, T. Stürmer, J. D. Huling, et al., “ Metformin at the Time of COVID-19 Infection and Risk of Long COVID: A Target Trial Emulation Study,” Journal of Medical Virology 98 (2026): e71190, https://doi.org/10.1002/jmv.71190.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.